Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Iluzanebart by Vigil Neuroscience for Unspecified Neurologic Disorders: Likelihood of Approval
Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Vigil Neuroscience's Iluzanebart?
Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases. According to...
Risk adjusted net present value: What is the current valuation of Vigil Neuroscience's Iluzanebart?
Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases. According to...